By Fineline Cube 
On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a specific object. The issuance price is set at 5.27 yuan per share, with the number of shares not exceeding 60,019,704, and the total funds raised are expected to reach up to 316.3 million yuan.
Company Overview
ChemPartner is dedicated to providing comprehensive services for drug discovery, development, and production to global pharmaceutical companies, biotechnology firms, and research institutions. As a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), ChemPartner plays a pivotal role in the pharmaceutical and biotech industries.
Strategic Capital Raising
The company’s decision to issue shares reflects its strategic focus on expanding operations and enhancing R&D capabilities. The funds raised will be allocated to advancing innovative drug development projects and strengthening global partnerships, further solidifying ChemPartner’s position in the CRO/CDMO sector.-Fineline Info & Tech